NeuroRx, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.neurorxpharma.com
NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis
Phase 2
Not yet recruiting
- Conditions
- PyelonephritisUrinary Tract Infections
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- NeuroRx, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT06128213
NRX-101 Expanded Access
- Conditions
- Bipolar Affective DisorderBipolar Depression
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- NeuroRx, Inc.
- Registration Number
- NCT05779267
Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- NeuroRx, Inc.
- Registration Number
- NCT04990466
NRX101 Glx Biomarker Validation Study
Phase 2
Completed
- Conditions
- Bipolar DepressionSuicidal Ideation
- Interventions
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2022-08-09
- Lead Sponsor
- NeuroRx, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03402152
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression
Phase 3
Active, not recruiting
- Conditions
- Bipolar DepressionSuicidal Ideation
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-01-11
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- NeuroRx, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT03396601
- Locations
- 🇺🇸
JP Smith Hospital, Fort Worth, Texas, United States
🇺🇸Research Centers of America, Hollywood, Florida, United States
NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation
Phase 3
Active, not recruiting
- Conditions
- Bipolar DepressionSuicidal Ideation
- Interventions
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- NeuroRx, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT03396068
- Locations
- 🇺🇸
JP Smith Hospital, Fort Worth, Texas, United States
🇺🇸Research Site, Birmingham, Birmingham, Alabama, United States
🇺🇸Research Centers of America, Hollywood, Florida, United States
NRX-101 for Bipolar Depression With Subacute Suicidal Ideation
Phase 2
Completed
- Conditions
- Bipolar DepressionSuicidal Ideation and Behavior
- Interventions
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- NeuroRx, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT03395392
- Locations
- 🇺🇸
iResearch Atlanta, LLC, Decatur, Georgia, United States
🇺🇸iResearch Savannah, Savannah, Georgia, United States
🇺🇸Peace Health Medical Group, Eugene, Oregon, United States
Sequential Therapy for the Treatment of Severe Bipolar Depression.
Phase 2
Completed
- Conditions
- Bipolar DepressionSuicidal IdeasSuicidal IdeationSuicide, Attempted
- Interventions
- Drug: NRX-101 Oral CapsuleDrug: Saline Solution Intravenous Infusion
- First Posted Date
- 2016-11-28
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- NeuroRx, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02974010
- Locations
- 🇺🇸
Research Site, Birmingham, Birmingham, Alabama, United States
🇺🇸Research Site, Charlotte, Charlotte, North Carolina, United States
🇺🇸Research Site, Houston, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath